在阿尔茨海默氏症小鼠大脑中细胞能量基因集群的相互作用
Raghavan Pillai Raju1, Lun Cai2, Alpna Tyagi3,4
1Medical College of Georgia, Augusta University, Augusta, GA, USA. rraju@augusta.edu.
Molecular neurobiology
|August 26, 2023
概括
这项研究揭示了阿尔茨海默病 (AD) 鼠标模型中显著的基因表达变化,突出显示了细胞能量和免疫反应的改变. 这些发现为AD病原和潜在的治疗点提供了新的见解.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是老年斑块和神经纤维状结.
- 线粒体功能障碍,氧化应激和神经炎症是AD病变发生的关键因素.
研究的目的:
- 为了研究5XFAD小鼠大脑中不同分子路径之间的交叉声,一个粉样蛋白病理模型.
- 为了确定与阿尔茨海默病相关的显著基因表达变化.
主要方法:
- 在5XFAD小鼠和野生型 (WT) littermates的大脑上进行了RNA测序 (RNA-seq) 分析.
- 用基因相互作用网络分析来探索差异表达基因之间的关系.
主要成果:
- 与WT相比,1288个基因在5XFAD小鼠大脑中显示出显著的表达变化.
- 氧化降解基因的下调,特别是线粒体基因,是一个突出的发现.
- 观察到免疫反应基因的升级,并确定细胞能量作为主要的基因相互作用集群.
结论:
- 与细胞能量和免疫反应相关的基因表达的显著变化发生在AD小鼠大脑中.
- 细胞能量成为5XFAD小鼠模型中受影响最明显的途径.
- 这些发现提供了一个关于阿尔茨海默病病原体中的分子路径交叉的全面视图.
更多相关视频
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
477
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212